Answers are grounded in this paper and cite their sources.
HCV infection treatment regimens are viewed from positions of HCV life cycle and replication, effects of NS3/4A protease inhibitors and NS5A/NS5B inhibitors on HCV strain replication. Evolution of HCV treatment regimens from its discovery to modern DAA agents had led to substantial progress although drug resistance poses a new issue to be addressed.
No takes yet. Share an insight, caveat, or question.
Малов et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: